Categories

Above the Fold

HEALTH PLANS/POLICY: It will stagger you to find out that health care competition may not result in better quality!

Now I want you all to sit down comfortably  and drink a glass of water before you read this article.  Says here (in a story cribbed from the academic journal Medical Care) that Health care competition may not result in better quality. The study found that HMOs in places where there was less competition between HMOs did better on HEDIS scores. Oddly those where there was more enrollment in HMOs also did better on HEDIS scores (though not as well on consumer satisfaction).  All suggesting that a single monopoly HMO probably does best of all on quality.  Um, does this sounds like anywhere we know? Well now you’ve all recovered from the shock, let’s review what little that we know on the subject.

a) Competition amongst health plans and HMOs is not about the competition to produce the best quality care. It’s about the competition to insure as many as possible of the people least likely to need it. Harsh but fair words.b) In general health plans have little ability to control what medical providers do, and providers are the ones who do the things that make up HEDIS scores. Consumer satisfaction with health plans has to do with customer service reps, not health care quality which the average consumer wouldn’t recognize even if it showed up as their prom date.c) The more health plans there are in an area the less each plan’s ability to get providers to do anything, as they’ll be responsible for a very small part of the provider’s businessd) As Porter, Enthoven and a host of other bright people have pointed out, competition such as it exists in the US system is in the wrong place (see point a).And e) no one in the real world, where people and employers vote with their money, cares about HEDIS or has even heard of it.

I hope no one working hard in a health plan feels too offended. Sorry for feeling bloody minded tonight, but my next chore is to do my taxes! I’m sure you understand!

HEALTH PLANS: Are there any winners from the high deductible games?

The LA Times had an article this weekend about how patients were leaving HMOs to go PPOs which were essentially high deductible plans. The article claims that the new trend is leaving HMOs in an Unstable Condition: as Members Bolt to Other Plans.

Ignoring the fact that it’s the same corporate parents who provide both types of insurance product, so the HMOs per se (with the possible exception of the still highly profitable Kaiser) are not exactly becoming "unstable", there are two connected but somewhat obscured issues here. The total cost of treating an HMO patient is still somewhat cheaper than treating a comparable PPO patient, but much more of that cost is now pushed onto the consumer/employee so the premiums are cheaper for the employer/payer. Where Blue Cross’ new high deductible plan called Tonik and other low price (but not low cost!) plans come in is that they are an attempt by one insurer or another to favorably  slant their overall risk profile — as insuring healthy people is a much easier way to make money than taking proper care of sick ones. This is not new. Prior to its sale to Aetna in 1996 US Healthcare was expert at paying off brokers to find them better risk groups in the early 1990s. Aetna forgot to use that technique when they bought them, but certainly has rediscovered how to improve their risk profile in the last five years. All plans have been playing this game forever, this is just a new variant. Look for the coda at the end of this article for more information about brokers being paid off by plans. (In the case of Aon, the pay-offs were allegedly at the insistence of the broker but you can imagine that they weren’t being paid bribes to deliver the groups with the worst risk profiles! Eliot Spitzer for one has noticed).

Meanwhile the AMA’s wet dream of an HSA with the consumer paying (a price of the doctors choosing!) at the point of service is plain wrong. I’ve been hearing this fantasy from physicians in focus groups since 1994! But the truth is that, even with the high deductible plans, payment will still go through the insurer and all the rigmarole that they put the providers through to get paid will still exist. It’s just for the high deductible plans the money will now come out of the consumer’s bank account.  In fact it’ll be harder for the provider to collect from those consumers without an HSA linked directly to their health plan’s account (which my guess is over 90% of HSA holders presently).

I know. I have one of these plans and when I had surgery last year I made all my providers wait several months until after my plan finished totally messing up my deductible calculations and finally got the amounts right before I paid out a penny! The providers still had to send in all the medical notes, I still got (mostly wrong) EOBs, I still had to spend hours and hours on the phone with confused and beleaguered customer service reps, etc, etc. The only difference was that when all was said and done the providers had to come after me for a big share of the money. Luckily I had the money set aside. How many Tonik members — supposedly young and relatively poor extreme-sports types — will be able to say the same?

Funnily enough I’m not even sure that the games pay off that well for the plans. In 2003 I was offered an underwritten PPO that was originally quoted at $63 a month for a $2000 deductible/$3,000 max out of pocket.  When they found out about my previous knee surgery the premium quote went up to nearly $400 a month! Instead I bought a short term plan (from a subsidiary of the same company!) for about $70 a month. And then when, as their underwriters had guessed correctly, I needed more surgery it all eventually cost (in terms of actual money paid out to providers) about $7000.  That would have been roughly the same as my original premium payments ($4,500) plus my maximum out of pocket ($3,000).  In other words for the original plan a $7,500 patient would have been one on which they’d have broken-even  but as I went with the non-underwritten plan that I assume is similar to Tonik, which didn’t quite cover so many conditions (e.g. no pregnancy coverage, and excluded diabetics, cancer patients, etc up front) , I paid about $3000 less in premiums.  So they lost money on me!  Were there no "bare-bones" short term plan available, aimed primarily at younger healthier people, I’d have probably ended up paying up for the more expensive version.  (Luckily I’m in a buying group now that gets me the $400 premium plan for closer to $200!)

Of course if all the health plans get this right then, while the risk pool will continue to fragment overall, more consumers will end up holding the bag. But it’ll eventually be a zero sum game for the insurers as they all have to figure out how play the risk-avoiding game as well as their competition, which will end up with all their risk profiles the same. Then they’ll have to think of the next bright idea to get a competitive edge! I smell consulting dollars….

CODA: Meanwhile if you want to know a little more about the games played by health plans to get the better risks, or perhaps to make sure that they don’t get stuck with the worst ones, take a look at this article that I swiped from Managed Care Week. (They don’t put out an online version but they sometimes reprint articles in AIS Health Business News.

Complaints filed by five state agencies against one of the nation’s largest insurance brokers offers a behind-the-scenes look at how insurers allegedly compensate brokers for steering insurance business.
Connecticut Attorney General Richard Blumenthal (D), Illinois Attorney General Lisa Madigan (D) and New York Attorney General Eliot Spitzer (D), along with state insurance commissioners in New York and Illinois, on March 4 said they reached a $190 million settlement with Aon Corp. for "soliciting and accepting kickbacks to steer business to favored insurers." The complaints outlined alleged payments made by health insurers including Aetna, Inc. and WellPoint, Inc. subsidiary Anthem Blue Cross and Blue Shield of Connecticut to Aon Corp. in order to win business from Aon’s clients.
The case never went to trial, and Aon said it admitted no wrongdoing or liability in the settlement.

As part of the agreement, Aon CEO Patrick Ryan apologized and acknowledged that some Aon staff members engaged in improper conduct. But he also said he did not agree with several allegations in the complaints.
The settlement was unveiled five months after Spitzer filed lawsuits against a major broker and four insurers in the property and casualty industry. That suit kicked off a nationwide probe into how brokers are compensated for steering business to one insurer over another.
According to Blumenthal’s complaint, employers paid Aon a fee to select "the best insurance coverage for the best price." But Aon made it clear to Aetna, Anthem and other insurers that their products would not be selected unless the insurers made additional "back-door" payments that "were folded into the overall premiums paid," the filing said.
These payments — which Blumenthal derided as "kickbacks," — "have the potential to compromise Aon’s objectivity and improperly influence its brokerage and consulting decisions by directing business to insurers that pay overrides and withholding business from those that do not," the complaint asserted.
The complaint also charged that Aon did not report the commissions, overrides and other payments to clients, and pressured insurers to omit such payments from their reports to employers on Internal Revenue Service Form 5500 and other documents.

Blumenthal’s complaint offered the example of Manchester, Conn., which paid Aon an annual fee of $14,350 to help it select health insurance for employees. The town’s request for proposals "specifically insisted that the winning broker only accept a commission from the town." Meanwhile, according to the complaint, Anthem was paying Aon over $1 million per year in various commissions, overrides and other payments. The complaint charged that "the steering evidently worked for, interestingly, Manchester, and every other Connecticut municipality that retained Aon Consulting for its health coverage, ended up with insurance from Anthem Blue Cross Blue Shield."
Aetna initially resisted paying override commissions to Aon, the complaint alleged. It quoted several internal Aetna e-mails and company managers. One e-mail said, "[Aon] made it clear that the lack of an override puts us at a severe disadvantage. That is evidenced by the fact that we haven’t written a case with them in several years." Another described a meeting in which one broker told the Aetna staff member, "You guys just don’t get [it], price and ease of administration is not the issue…it’s my compensation."
According to the complaint, Aon brokers said the solution was simple: Aetna should "load the rates for additional comp[ensation] and you’ll start to get the business. If the comp is right, they will sell the rates," according to an Aetna manager quoted in the Blumenthal complaint. "He told us to load our rates 5-10% (give him 1/2) and we’d get all his business."

Such arrangements were successful, the complaint alleged. "As one Aetna executive put it, overrides have the potential to ‘take away the objectivity consultants are so protective of.’"
Blumenthal’s complaint indicated that Aetna eventually "began to adapt," developing payment structures that allowed the insurer to pay Aon commissions that were not reported to employers.
Brokers Allegedly Wanted Payments Hidden
The Connecticut complaint asserted that brokers continued to insist on concealed arrangements even as regulators stepped up scrutiny into commission payments. The filing quoted an e-mail sent by a broker to Aetna. "As the discussion around disclosure of override contracts heats up we want to position these as arrangements as profit sharing of the overall book and not tied to a specific account."
Spitzer’s complaint outlined similar experiences in New York. Herkimer County, N.Y., which purchases benefits for 1,000 employees, paid Aon more than $78,153 over a five-year period to help it buy "stop-loss" coverage for protection from catastrophic health claims.
"In 2001, the lowest bidder for the Herkimer business would have been [Excellus] BlueCross BlueShield," Spitzer’s complaint said. "But since the coverage offered by Blue Cross would not have generated a 15% commission for Aon Consulting, it never gave Blue Cross the chance to bid." When Herkimer eventually demanded that the Blues plan be permitted to bid on business, "Aon altered it [i.e., the Blue Cross bid] by adding the 15% commission without disclosing the change to Herkimer," it alleged.

As part of its settlement, Aon agreed to create a $190 million fund to compensate eligible U.S. clients with policies begun or renewed between Jan. 1, 2001, and Dec. 31, 2004. It also promised to commit to "new business practices that include heightened disclosure of remuneration and the elimination of practices that may have posed conflicts of interest."
Anthem spokesperson James Kappel said he could not comment on the suits since Anthem was not a target. But, he added, "As a company, we do not engage in the practice of bid rigging or any other improper bidding practices. Any bonuses that are paid to brokers are based on persistency [the percentage of clients that renew coverage] and the growth of their overall book of business."
"Aetna firmly believes that disclosure of compensation arrangements with brokers is in the best interest of our customers, the broker community and the insurance marketplace," the insurer said. "In 2004, we began requiring brokers to inform their customers about compensation agreements, and we have recently published our expectations regarding disclosure of compensation on our Web site."
(Reprinted from the March 21, 2005, issue of MANAGED CARE WEEK)

HEALTH PLANS/PHYSICIANS: More patient confidentiality probs at SF Bay area institutions, with UPDATE

So not long after the mess with Kaiser and the Gadfly appears to be heading to a court solution, there are two more weird breaches of patient confidentiality both demonstrating that it’s not technology but the physical security of data and the dealings of employees that are the riskiest part of keeping confidential medical information confidential. 

The first story is really strange.  Apparently a contractor working for Kaiser had some patient data, and tried to recycle carbon paper for their fax machine at a local copy store. But instead of being recycled, somehow it ended up in the paper supply and was sold to another customer who  discovered that instead of being blank, their fax paper had patient data from Kaiser and a Reno ambulance firm. In the end the customer returned it to the copy shop and no harm appears to have been done. (The full story is the second story here) But then again it just shows that this stuff can get out in ways that are hard to imagine, and perhaps every person handling patient date needs to buy a shredder.  I know that I carried around patient date from my 1992 graduate thesis work and only got around to shredding it a few years later!

The other incident is more sinister, and again it appears that the health care organization, in this case San Jose Medical Group, did nothing wrong. However, someone broke into their facility and stole three laptop computers which had patient information and social security numbers on them.  They don’t know if these computers were stolen as a target for identity theft, although they have written to all the affected patients asking them to check with their credit bureaus, or whether this was done just to steal the computers.  But all the same, my source is one angry patient, and I don’t know whether or not this was a HIPAA violation.  Here’s the police report.

All in all a reminder to health care organizations that electronic security is not enough.  Incidentally if you steal my laptop you have to know two passwords to make it start-up and then work for you, and a third to get into my password storing application Roboform.  I suggest anyone reading this who uses a laptop makes sure they are using the root password function that is available by hitting F8 (or a similar key) before Windows starts, and setting a system password required on start-up.

UPDATE: The SJ Merc has more info about this in a story today. While San Jose Medical Group officials seem to believe someone from the outside stole the computers because they were new, the police report doesn’t seem to mention a forced entry. And there’s no word on whether the data was secured with a password, although it appears not to have been encrypted. It does seem that given that a laptop by definition can be mobile (and therefore easily lost), sensitive data should either be encrypted or somehow electronically secured within it.

PHARMA: Squaring the circle on Pfizer’s job cuts

Over at the Pharma Marketing Blog and on the Pharma Marketing list-serv John Mack is confused about Pfizer’s real intentions.

Is Pfizer eliminating up to 11,000 sales rep jobs or isn’t it? A WSJ article states: "In another cost-cutting plan, Pfizer plans to streamline its U.S. force of 11,000 sales representatives." Then in the next paragraph it also says "Chief Executive Hank McKinnell didn’t give details on the job cuts, but did say few jobs would be lost in the company’s sales division." (Significant cuts in a force with) 11,000 jobs seems like more than a "few" so I am at a loss to understand what Hank actually said or meant.

John asked for the list’s take on this.  Remembering this article from THCB regular The Industry Veteran in which he suggested that Hank made about $50m a year (even though Forbes says it’s closer to $17m), I suggested that the solution to John’s quandary is simple: If Hank makes give or take $50m a year (as The Veteran believes), and a sales rep makes $100K, then it takes 500 sales reps to equal one CEO.  So if you fire 11,000 reps you’re really only cutting  22 "real" jobs. They’re never going to cut the whole workforce so any amount is less than 22 and that’s just a "few" in Hank’s terms.

(You are all welcome to do the real math if you want, but I’m no good at dividing by 17!!)

PHARMA: FDA orders Pfizer to withdraw Bextra

This just in at the Health Care Blog’s New York Desk … The U.S. Food and Drug Administration has ordered Pfizer to withdraw Bextra from the market and urged "the possible strongest warning" for it’s fellow Cox-2 inhibitor Celebrex.   See the AP story for details.UPDATE: Read the FDA press release here.

POLICY/POLITICS: Wanna be physician of the year? Pay Bush $1,500

AwardIn a hard hitting investigation ABC news is shocked, shocked(!) to find out that such an honorable profession as that of physicians is not above creating lots of phony awards so that everyone can win one.  The joke is that the hundreds of physicians who won the "Physician of the year" award found that the title came not from a fake medical college or diploma mill, but straight from the Republican National Committee. Well if they’re dumb enough not only to pay up but also to go to Washington DC for a couple of days to collect, why shouldn’t Tom Delay take their money — after all the half mill or so he needs to pay his wife has to come from somewhere? (Hat tip to Kevin MD & John P for this one)

BLOGS: Orac hosts Tangled Bank

Over at his Respectful Insolence (a.k.a. "Orac Knows") blog that usually focuses on public health, Orac is hosting The Tangled Bank XXV, which is kind of a Grand Round for scientists.  While frankly I don’t care too much for basic science (spot the guy who got kicked out of physics class and retreated to history at age 15), the writing — in the style of a very pissed off author submitting his work to an academic journal — is hysterical.  And if you check the links closely you’ll see one with a most unlikely concurrence of scientists and babe-models.

POLICY/PHYSICIANS: Beauty Contest

Modern Physician is running a poll where you can go and vote for the
best looking, err…most powerful physician executive in American
health care.  It’s actually quite a tricky call. For example is Tom Frist from HCA the most powerful doc because he and his family own the biggest hospital chain and have a sibling who runs the Senate? (For that matter why isn’t Bill on the list as overall he’s obviously by the far the most powerful MD in the nation even if it hasn’t got much to do with his increasingly dubious behavior when he claims to be using his medical training). Is Jack Rowe from Aetna or Bill McGuire at United Health the most powerful because everyone at one the biggest insurers has to do what they  say (plus Bill’s probably got the most money!)? But maybe as the doc preaching the word of disease management at the single biggest insurer Sam Nussbaum (Wellpoint) is now the most powerful?

But then again while I don’t think Carolyn Clancy (AHQR) is that powerful, and that’s a bad thing for American health care, Mark McClellan (CMS) has got the biggest stick and seems to be prepared to use it in the interest of promoting "the right things" from Medicare in the years to come.  On the other hand Don Berwick (IHI) or Jack Wennberg (Dartmouth) have probably had more influence in promoting P4P and the quality movement that McClellan’s now espousing than anyone else.  Influence?  For sure. Power?  Well in some ways they wouldn’t have had the time they’ve had to build up their influence if they’d had the power to achieve their goals!

Maybe it’s some new fangled IT whiz who’s got the most power — readers in one poll last year called David Brailer the most powerful man in all of health care — then he didn’t even get $50m from the Congress to fund his office so I’m not convinced that he has any real power.  Maybe Blackford Middleton at Partners is the most powerful, showing that real EMRs can be brought into the ivory tower (Well I met a bunch of his serfs last night and they all seemed real scared of him!!). Molly Coye is great, but for all Healthtech’s influence with the big hospitals her days of real power were back when she struck fear into the heart of Medi-Cal managed care plans (or at least would have done if they’d figured out what she was up to!).

Is Jack Lewin at the CMA (the largest state medical association) the most powerful? Hmm…you don’t hear much about Michael Maves at the AMA either for that matter.

So my vote this year for the first and last time will be for someone who’s not in the mainstream.  David Graham, the FDA gadfly, is pretty much responsible for destroying Vioxx and crippling Merck, and has had a hand in causing problems for the rest of big pharma. I can’t vote for him as he’s not on the list, but Sid Wolfe shares the same views so I can vote for him and call it a team vote. That’s real power even if its effervescent and more destructive than constructive (although something constructive may yet come out of all their work).

But overall this tells me that physicians are just not that powerful in health care as big names. It’s not the star power here that counts. It’s the collective behavior of all the doctors in practice and the power they exert in decisions they make every day that still more than anything else really determines what happens in American health care.

 

POLICY: Uninsured number will rise, but maybe not enough

In an article in Health Affairs today called It’s The Premiums, Stupid Gilmer and Kronick project the numbers of the uninsured through 2013. Kronick, BTW was a co-author with Alain Enthoven of some of his market-based consumer choice articles, though he seems to have moved leftwards since the early 1990s.   Essentially they forecast that there will be a continued price effect with low and middle-income workers continuing to be squeezed out of insurance as the costs go up.  For the human side of this, take a look at the LA Times article which assessed this phenomenon yesterday. For the numbers, Kronick and Gilmer say:

Based on the
projected growth rates for health spending and personal income, we
estimate that the rate of uninsured non elderly workers will increase by
4.0 percentage points to 27.8 percent in 2013. We estimate that the
uninsurance rate among all nonelderly Americans will increase by 3.3
percentage points to 20.5 percent in 2013. With an expected population
of 271 million people under age sixty-five in 2013, we estimate that
there will be fifty-six million uninsured Americans in this age group,
an increase of thirteen million over the CPS estimate for 2002. Of this
estimated increase, 8.6 million occurs because of the expected increase
in the proportion of the population that is uninsured, and 4.4 million
because of an increase in population size.

The problem is that while there are countless stories of misery behind these numbers, and some real costs to being uninsured in terms of both access to care and worse health status —  not to mention the corresponding increase in people being severely underinsured — this may not be enough to change things.  Vic Fuchs at Stanford always used to say that we needed a national crisis to change the health system.  Adding a couple more million people — and they are poorer, more marginalized people than the typical voter — to the uninsured numbers each year isn’t going to change too much.  If however, things are getting worse, and we see these numbers increase at a faster rate — particularly amongst white middle income males in their 50s (i.e. Republican voters) — then there might be some real change coming up in 4-8 years.  I think that’s an equally plausible scenario, but if Gilmer and Kronick are right, then it’s probably more of the dreary same.

PHARMA: Where are the orphan cancer drugs? by The Industry Veteran

Greg Pawelski’s recent posting here about whether cancer care could improve has drawn several responses, many of which I’m trying to redirect back into the comments section.  One, however,  that deserves its own posting is from our old friend The Industry Veteran who wonders whether the current model of big pharma itself can sustain itself in the kind kind of designer-drug world Greg is proposing:

Greg Pawelski makes a good point in his post, specifically, that the economic
model under which Pharma companies develop oncology products may be inimical to
the individualized treatment approaches required for the disease(s).  I suspect
that the figurative lumber rooms of the Big Pharma companies are stacked with
discontinued oncology compounds that proved wonderfully effective and tolerable
for 5%-10% of the target candidates but, sadly, they were terribly toxic or no
better than placebo for the others.  In fact, I know that’s the case.  Not long
ago I completed a study for a client to find why the companies are so reluctant
to out-license these moribund compounds.  The overwhelming answer, the one that
dwarfs all the others, is ego of the fiduciary executives.  The executives feel
they would invite serious job trouble by out-licensing an abandoned compound to
a small startup that proceeds to make it a successful brand.
While
Pawelski deplores the one-size-fits-all requirement, that constitutes the
standard among Big Pharma for launching a product. 

Today the Big Pharmas will
curtail development of a product with projected, peak year, global sales of less
than $850 million.  Anything less will not sustain their high fixed costs or
permit the economies of scale on variable expenses that represents their
comparative advantage.  When BusinessWeek asked Pfizer’s CEO Hank
McKinnell if the era of the blockbuster (and the giant Pharmas created to
support such megaliths) has passed, he replied, “Anybody who says that doesn’t
understand our business.”  A small company, however, can derive a large return
on equity/sales/assets from a product that successfully treats 5%-10% of a
comparatively small, target population.  The CEO of such a company probably
won’t receive $50 million annual compensation the way Mr. McKinnell does, but
its stockholders and a reasonable number of patients can benefit when a Celgene
takes an abandoned and despised compound (thalidomide, developed as a
tranquilizer for pregnant women) and brings it to market as a major therapy for
multiple myeloma.

I suspect this dilemma will resolve itself as the
pharmaceutical industry evolves into what Oracle’s CEO, Larry Ellison, once
called the Hollywood approach to drug development.  I’ve written about this
before and don’t wish to repeat myself, but basically this involves the Big
Pharmas limiting themselves to acting as sources for development funding and
distribution, while independent producers (biotechs? specialty companies?) buy
the properties and develop them.  Movies today can successfully reach smaller,
more segmented audiences than the big Hollywood studios ever could during the
Mickey Rooney, Judy Garland days.  Unfortunately a lot of people will needlessly
die of cancer before Andy Hardy grows up and tells Louis B. Mayer to go screw
himself.  But hey, in a country that twice elects a wannabe redneck as
president, the market is sacrosanct and its pace of Darwinian change is all we
can expect.

assetto corsa mods